CAR T-Cell Therapy Leads to Shorter Hospital Stays, Lower Nonpharmacy Costs Despite High Overall Cost
CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them. Although the total and pharmacy cost to hospitals for the index procedure were higher when patients received CAR T-cell therapy than when they underwent stem cell transplant (SCT), nonpharmacy costs were lower, according to findings from a retrospective study published in Blood.1
Findings from the real-world evidence study showed that the total mean cost in USD of the index procedure was $371,136 for CAR T-cell therapy, $96,515 for autologous SCT, and $169,269 for allogenic SCT.
